Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Published Online: 2019-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: A Cervantes•A Chaudhry•A Smolin•A Strickland•AS Lee•Alberto Sobrero•Alfredo Falcone•Anne Uyei•B Lesperance•B Ma•B Tan•CG Ponce•Cathy Eng•D Chu•D Cunningham•E Chmielowska•E Maiello•E Szutowicz-Zielinska•E Van Cutsem•F Couture•Fortunato Ciardiello•G Luppi•G Marx•Guillem Argilés•Ilsung Chang•J Asselah•J Cultrera•J Davies•J Kortmansky•J Lee•J Marshall•J Reeves•JB Ahn•JL Canon•JM Tabernero•JO Park•JO Streb•JS Valera•Johanna Bendell•K Chang•K King•KO Lam•Louise Roberts•M Dvorkin•M Kozloff•M Nechaeva•M Van den Eynde•M Vickers•M Womack•M Wroblewska•Maria Di Bartolomeo•Mark Kozloff•Marwan Fakih•N Pavlakis•N Segal•Neil H Segal•Niall C Tebbutt•P Potemski•P Vergauwe•PJ Cuyle•R Kerr•R Mandanas•R Young•RG Carbone•RV Garcia•S Badarinath•S Baijal•S Begbie•S Berry•S Dowden•S Mullamitha•S Raouf•S Siena•SH Cho•TY Kim•Tae Won Kim•V Ganju•YJ Cha•Yibing Yan
